Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486401 | 0.88 | DYRK1A (0.43) | FYNRIPK1 | |
| SCHEMBL3486481 | 0.87 | FYN (0.47) | KDM4EALDH1A1FYN | |
| SCHEMBL3487008 | 0.82 | PIK3CD (0.39) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3486636 | 0.81 | KIF11 (0.38) | KDM4EF2RL3 | |
| SCHEMBL13498805 | 0.77 | MAP3K5 (0.56) | RIPK1 | |
| Trifluoroacetic Acid SCHEMBL3486117 | 0.77 | MAP3K5 (0.53) | RIPK1 | |
| SCHEMBL3486521 | 0.76 | ALDH1A3 (0.41) | KDM4EALDH1A1HPGD | |
| SCHEMBL10857864 | 0.73 | KDM4E (0.60) | KDM4EALDH1A1CYP1A2CYP3A4GABRA1 | |
| Bromide SCHEMBL10851397 | 0.72 | KDM4E (0.58) | KDM4EALDH1A1CYP1A2CYP3A4GABRA1 | |
| SCHEMBL3486125 | 0.71 | KCNH2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | KDM4E 898/4885ALDH1A1 794/4885CYP1A2 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.